Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation
Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation https://www.diffusionpharma.com/wp-content/themes/crocal/images/empty/thumbnail.jpg 150 150 Diffusion Pharmaceuticals Inc. https://www.diffusionpharma.com/wp-content/themes/crocal/images/empty/thumbnail.jpgCHARLOTTESVILLE, Va., July 26, 2022 (GLOBE NEWSWIRE) — Diffusion Pharmaceuticals Inc.
https://investors.diffusionpharma.com/News/news-details/2022/Diffusion-Pharmaceuticals-to-Initiate-Phase-2-Trial-in-Patients-with-Glioblastoma-Multiforme-Incorporating-Innovative-Imaging-Methodology-to-Evaluate-Tumor-Oxygenation/default.aspx